Table 2.
Patients and treatment characteristics.
| Number | % | |
|---|---|---|
| All patients | 123 | 100 |
| Age (median, range), years | 64, 46–78 | |
| pT | ||
| 1c | 0 | 0 |
| 2a | 1 | 0.8 |
| 2b | 2 | 1.6 |
| 2c | 14 | 11.4 |
| 3a | 61 | 49.6 |
| 3b | 41 | 33.3 |
| 4 | 4 | 3.3 |
| pN | ||
| 0 | 79 | 64.2 |
| 1 | 18 | 14.6 |
| X | 26 | 21.1 |
| Perineural infiltration | ||
| No | 47 | 38.2 |
| Yes | 76 | 61.8 |
| PSA before surgery (median, range), μg/L | 8.8, 0.4–55.0 | |
| PSA after surgery (median, range), μg/L | 0.06, 0.01–0.90 | |
| Histopathologic grade, Gleason score | ||
| 2–6 | 23 | 18.7 |
| 7 | 69 | 56.1 |
| 8–10 | 31 | 25.2 |
| Lymphadenectomy | ||
| No | 26 | 21.1 |
| Yes | 97 | 78.9 |
| Interval surgery-radiotherapy (median, range), months | 4 (2–9) | |
| Radiotherapy dose to prostatic bed, Gy | ||
| 64.8 | 18 | 14.6 |
| 70.2 | 105 | 85.4 |
| Elective nodal irradiation | ||
| No | 52 | 42.3 |
| Yes | 71 | 57.7 |
| Adjuvant hormonal therapy | ||
| No | 38 | 30.9 |
| Bicalutamide | 48 | 39.0 |
| LH-RH analogue | 37 | 30.1 |